CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy

CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy

Tumor vaccines trigger tumor-specific immune responses to prevent or treat tumors by activating the hosts’ immune systems, and therefore, these vaccines have potential clinical applications. However, the low immunogenicity of the tumor antigen itself and the low efficiency of the vaccine delivery sy...

Full description

Bibliographic Details
Main Authors: Shengyang Liu, Jiayan Wu, Yuanji Feng, Xiaoya Guo, Tong Li, Meng Meng, Jie Chen, Daquan Chen, Huayu Tian
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2023-04-01
Series:Bioactive Materials
Subjects:
CRISPR–Cas9
Dual-bioengineered cell membrane
Immune checkpoint blockade
Nanovaccine
Tumor immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2452199X22004133

Internet

http://www.sciencedirect.com/science/article/pii/S2452199X22004133

Similar Items